Pioneering biologics with precision to redefine treatment for millions
Fortvita is focused on investigating biologics with smarter design and agile innovation, with the goal of translating next-generation therapies from concept to clinic.
What We Do
Pursuing scientific solutions for global healthcare needs
Fortvita Biologics is the U.S.-based biopharmaceutical member of Innovent Biologics (HKEX: 01801), formed to bring Innovent’s clinical-stage and approved therapies to patients outside China.
Backed by Innovent’s proven discovery, development, manufacturing, and commercialization capabilities, Fortvita advances innovative biologic therapies for patients worldwide through global clinical development, strategic partnerships, and international commercialization.
Our pipeline spans oncology, cardiovascular and metabolic (CVM) diseases, autoimmune disorders, ophthalmology, and other serious diseases. In oncology, we are advancing next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) programs, supported by expertise in protein engineering, structure-based drug design, and multispecific antibody technologies. Beyond oncology, we are applying these scientific capabilities to develop therapies for diseases with significant unmet medical need.
Pipelines
Pipelines designed with focused innovation
Our pipeline reflects a strategic and focused approach to innovation, advancing programs that explore novel mechanisms in immunotherapy and targeted delivery. Current assets include bispecific antibodies and antibody-drug conjugates (ADCs) directed at PD-1, IL-2, DLL3, CLDN18.2 and other emerging targets, with clinical and preclinical development spanning multiple tumor types including lung, gastric, pancreatic, colorectal, and melanoma.
Our Mission
Empowering patients by advancing high-quality, innovative biopharmaceuticals with urgency and scientific rigor
Headquartered in the San Francisco Bay Area, Fortvita is advancing innovative biologic therapies through a global clinical development network spanning the United States, Australia, Europe, and Asia-Pacific. Our pipeline targets some of the world’s most serious diseases, including cancer, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmic conditions, with the goal of expanding access to transformative medicines for patients worldwide.
